InflaRx (IFRX) Long-Term Debt Issuances (2019 - 2026)
InflaRx's (IFRX) quarterly Long-Term Debt Issuances came in at -$89315.9 in Q2 2026, up 20.94% year-over-year from -$73849.2 in Q2 2025, and down 2.14% quarter-over-quarter from -$87443.0 in Q1 2026.
Powered by 
Analysis
InflaRx (IFRX) Long-Term Debt Issuances (2019 - 2026) Analysis & Trends
InflaRx has disclosed Long-Term Debt Issuances across 8 years of filings, most recently posting -$89315.9 for Q2 2026.
- In Q2 2026, Long-Term Debt Issuances rose 20.94% year-over-year to -$89315.9; the TTM figure through Jun 2026 stood at -$360729.8 (up 16.03% YoY), while the FY2025 annual figure was -$404001.3, up 2.59% from the prior year.
- Long-Term Debt Issuances came in at -$89315.9 for Q2 2026 at InflaRx, down from -$87443.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of -$84656.2 in Q4 2025 to a low of -$115600.7 in Q2 2024.
- Average Long-Term Debt Issuances over 5 years is -$99321.7, with a median of -$99967.0 recorded in 2023.
- Year-over-year, Long-Term Debt Issuances decreased 16.6% in 2024 and climbed 20.94% in 2026.
- Over 5 years, Long-Term Debt Issuances stood at -$93187.4 in 2022, then dropped by 9.57% to -$102108.8 in 2023, then dropped by 2.53% to -$104689.2 in 2024, then climbed by 19.14% to -$84656.2 in 2025, then declined by 5.5% to -$89315.9 in 2026.
- Per Business Quant data, the three most recent Long-Term Debt Issuances figures were -$89315.9 in Q2 2026, -$87443.0 in Q1 2026, and -$84656.2 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.32 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | -89,315.88 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -89,315.88 |
| Mar 31, 2026 | -87,442.99 |
| Dec 31, 2025 | -84,656.23 |
| Sep 30, 2025 | -99,314.74 |
| Jun 30, 2025 | -112,977.50 |
| Mar 31, 2025 | -105,290.48 |
| Dec 31, 2024 | -104,689.22 |
| Sep 30, 2024 | -106,628.33 |
| Jun 30, 2024 | -115,600.65 |
| Mar 31, 2024 | -93,107.72 |
| Dec 31, 2023 | -102,108.85 |
| Sep 30, 2023 | -102,636.66 |
| Jun 30, 2023 | -99,143.30 |
| Mar 31, 2023 | -100,619.36 |
| Dec 31, 2022 | -93,187.35 |
| Sep 30, 2022 | -91,831.61 |
| Jun 30, 2022 | -97,324.11 |
| Mar 31, 2022 | -101,915.00 |
| Dec 31, 2021 | -101,854.60 |
| Sep 30, 2021 | -104,343.34 |